Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 25Carcinoma, Non-Small-Cell Lung 6Melanoma 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

Cetuximab 5Bevacizumab 4pembrolizumab 3Leucovorin 3Irinotecan 3Fluorouracil 3trifluridine tipiracil drug combination 2trastuzumab deruxtecan 2larotrectinib 2encorafenib 2binimetinib 2Trastuzumab 2Oxaliplatin 2Nivolumab 2HMPL-013 2Afatinib 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1sotorasib 1sapanisertib 1relatlimab 1regorafenib 1pralsetinib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Colorectal Neoplasms × pembrolizumab × Clear all
NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02563002 2024-10-03

KEYNOTE-177

Merck Sharp & Dohme LLC

Phase 3 Completed
307 enrolled 16 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡